Illumina has announced the completion of its acquisition of SomaLogic, a data-driven proteomics technology company, in a deal valued at USD 350 million in cash, with additional milestone-based payments of up to USD 75 million.

The acquisition enhances Illumina’s multiomics strategy by integrating SomaLogic’s proteomics capabilities into its existing genomics platform. The combined offering aims to provide scalable, high-resolution insights across genomics and proteomics, enabling researchers to accelerate drug discovery and improve healthcare outcomes.

Jacob Thaysen, Chief Executive Officer of Illumina, described the acquisition as a milestone in executing the company’s 2024 multiomics strategy. He noted that combining SomaLogic’s differentiated proteomics technology with Illumina’s global reach and innovation leadership will enable customers to extract deeper biological insights from every sample.

SomaLogic’s portfolio includes the SomaScan Proteomics Assay, SomaSignal Tests and advanced protein analysis technologies that provide insights into protein function, interactions and modifications. When integrated with Illumina Protein Prep, Dragen software and Illumina Connected Multiomics, customers will gain access to comprehensive, large-scale multiomic datasets with flexible workflows tailored to their research needs.

The acquisition builds on a co-development partnership that began in late 2021, when the companies agreed to bring the SomaScan assay onto Illumina’s high-throughput Next-Generation Sequencing (NGS) platforms. With the transaction now complete, Illumina is positioned to expand its presence in the rapidly growing global proteomics market.

Illumina stated it will continue supporting SomaLogic customers, service providers and existing partnerships as it integrates the business into its product roadmap. The company also reaffirmed its commitment to maintaining an open and accessible NGS platform.

The transaction was funded through cash on hand and Illumina plans to discuss the financial implications during its upcoming earnings call scheduled for February 5, 2026.

The company cautioned that forward-looking statements related to the acquisition are subject to risks, including integration challenges, market growth uncertainties, competitive pressures and customer adoption trends, as detailed in its filings with the U.S. Securities and Exchange Commission.